Renexxion Ireland Innovation
There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in  a wide range of these disorders. 

It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required.

Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).

Renexxion Ireland Ltd

Renexxion Ireland Ltd's headquarters in Roscrea, Ireland

Description

People (1)

Peter Milner

Jobs